NasdaqGM - Nasdaq Real Time Price USD

Protagonist Therapeutics, Inc. (PTGX)

44.41
+0.64
+(1.46%)
At close: May 15 at 4:00:00 PM EDT
43.91
-0.50
(-1.13%)
Pre-Market: 7:00:41 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
207,801
434,433
60,000
26,581
27,357
Operating Expense
180,577
181,590
153,652
157,954
153,202
Operating Income
27,224
252,843
-93,652
-131,373
-125,845
Net Non Operating Interest Income Expense
29,512
26,315
14,898
4,060
443
Other Income Expense
351
250
-201
-80
-149
Pretax Income
57,087
279,408
-78,955
-127,393
-125,551
Tax Provision
894
4,220
0
0
0
Net Income Common Stockholders
56,193
275,188
-78,955
-127,393
-125,551
Diluted NI Available to Com Stockholders
56,193
275,188
-78,955
-127,393
-125,551
Basic EPS
0.87
4.47
-1.39
-2.60
-2.71
Diluted EPS
0.78
4.23
-1.39
-2.60
-2.71
Basic Average Shares
62,094.02
61,566.99
56,763.56
49,042.23
46,322.91
Diluted Average Shares
64,919.84
65,077.72
56,763.56
49,042.23
46,322.91
Total Operating Income as Reported
27,224
252,843
-93,652
-131,373
-125,845
Total Expenses
180,577
181,590
153,652
157,954
153,202
Net Income from Continuing & Discontinued Operation
56,193
275,188
-78,955
-127,393
-125,551
Normalized Income
56,193
275,188
-78,955
-127,393
-125,551
Interest Income
29,512
26,315
14,898
4,060
443
Interest Expense
--
--
--
0
0
Net Interest Income
29,512
26,315
14,898
4,060
443
EBIT
27,224
252,843
-93,652
-131,373
-125,845
EBITDA
30,122
255,738
-90,340
-128,004
-123,070
Reconciled Depreciation
2,898
2,895
3,312
3,369
2,775
Net Income from Continuing Operation Net Minority Interest
56,193
275,188
-78,955
-127,393
-125,551
Total Unusual Items Excluding Goodwill
0
--
--
0
0
Total Unusual Items
0
--
--
0
0
Normalized EBITDA
30,122
255,738
-90,340
-128,004
-123,070
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 8/11/2016

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

MLTX MoonLake Immunotherapeutics
37.66
+1.81%
 
CRNX Crinetics Pharmaceuticals, Inc.
31.21
-0.26%
 
RYTM Rhythm Pharmaceuticals, Inc.
60.18
+5.06%
 
SRRK Scholar Rock Holding Corporation
30.83
+0.95%
 
AKRO Akero Therapeutics, Inc.
39.96
+5.49%
 
CYTK Cytokinetics, Incorporated
29.84
-0.53%
 
IDYA IDEAYA Biosciences, Inc.
17.31
+1.23%
 
BBIO BridgeBio Pharma, Inc.
33.74
+0.24%
 
KYMR Kymera Therapeutics, Inc.
30.02
+0.91%
 
ACLX Arcellx, Inc.
58.45
-0.97%